TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9157756
Drug: Tizanidine (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tizanidine (12 mg/day)
Study: 9157756
Drug: Placebo (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (12 mg/day)
Study: 8228368
Drug: Trimethoprim-sulfamethoxazole (TMP-SMZ)
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (TMP-SMZ) (160/800 mg)
Study: 30753384
Drug: Nitazoxanide (NTZ)
Normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitazoxanide (NTZ) 600 mg twice daily for age ≥12 years; 200 mg for age 4-11 years; 100 mg for age 1-3 years for 5 days
Study: 27477534
Drug: 1 per
Normalized name: ALOE VESTA 2-N-1 PERINEAL CLEANSER SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 per cent clotrimazole solution
Study: 18412024
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (Loprax) 400 mg cefixime
Study: 18412024
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation 400 mg cefixime
Study: 8624641
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 15 mg weekly, increased to 25 mg for poor responders
Study: 2869996
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin regimen designed to maintain near‐normal glycemic levels
Study: 2869996
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with up to two insulin injections daily
Study: 30536595
Drug: sacubitril/valsartan 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: sacubitril/valsartan 400 mg
Study: 17060062
Drug: olmesartan 20
Normalized name: olmesartan 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: olmesartan 20 mg
Study: 30180960
Drug: Combination simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination simvastatin (40 mg)/ezetimibe (10 mg)
Study: 30180960
Drug: Simvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (40 mg) alone
Study: 24021896
Drug: Bromfenac ophthalmic
Normalized name: bromfenac ophthalmic
DrugBank: Bromfenac (DB00963)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bromfenac ophthalmic solution 0.07%
Study: 16060219
Drug: NaFeEDTA-fortified soy
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaFeEDTA-fortified soy sauce (29.6 mg Fe/100 ml)
Study: 12803733
Drug: Rosiglitazone 8
Normalized name: rosiglitazone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone 8 mg/day
Study: 12398960
Drug: Rosiglitazone 8
Normalized name: rosiglitazone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone 8 mg/day plus atorvastatin 10 mg/day
Study: 12398960
Drug: Rosiglitazone 8
Normalized name: rosiglitazone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone 8 mg/day plus atorvastatin 20 mg/day
Study: 2538499
Drug: Nedocromil sodium,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nedocromil sodium, 4 mg
Study: 4616804
Drug: Oxolinic acid
Normalized name: oxolinic acid
DrugBank: Oxolinic acid (DB13627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxolinic acid (750 mg twice-daily for 14 days)
Study: 4616804
Drug: Ampicillin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin (500 mg 3-times daily for 14 days)
Study: 12611485
Drug: G-CSF 5
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF 5 microg/kg per day
Study: 15848703
Drug: ATG-Fresenius (4-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATG-Fresenius (4-6 mg/kg body weight)
Study: 15848703
Drug: Thymoglobulin (1.5-2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymoglobulin (1.5-2.5 mg/kg body weight)
Study: 11932960
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg itraconazole with 400 mg of didanosine (encapsulated, enteric-coated bead formulation)
Study: 11932960
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg fluconazole with 400 mg of didanosine (encapsulated, enteric-coated bead formulation)
Study: 2545979
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy (CAV)
Study: 2545979
Drug: Sequential chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential chemotherapy using three different drug combinations
Study: 795456
Drug: Propranolol (Inderal)
Normalized name: propranolol Extended Release Oral Capsule [Inderal]
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol (Inderal) 20 mg
Study: 795456
Drug: Propranolol (Inderal)
Normalized name: propranolol Extended Release Oral Capsule [Inderal]
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol (Inderal) 40 mg
Study: 795456
Drug: Propranolol (Inderal)
Normalized name: propranolol Extended Release Oral Capsule [Inderal]
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol (Inderal) 80 mg
Study: 30724059
Drug: Combined sea
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined sea salt-based oral rinse with Xylitol and lysozyme
Study: 28476814
Drug: Bevacizumab (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (7.5 mg/kg i.v. on day 1) plus gemcitabine (1,200 mg/m2 i.v. on days 1‐8)
Study: 28476814
Drug: Bevacizumab (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (7.5 mg/kg i.v.) and cisplatin (60 mg/m2 i.v.) plus gemcitabine (1,000 mg/m2 i.v. on days 1‐8)
Study: 25912693
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard pharmacotherapy)
Study: 21756210
Drug: Oral lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral lorazepam 2 mg (LOR)
Study: 19364310
Drug: 5 mg/d
Normalized name: Arixtra 5 mg/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/d of oral folic acid
Study: 16362296
Drug: Paclitaxel with
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel with 1,200 mg clindamycin
Study: 11158211
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid added to antihypertensive therapy
Study: 11555501
Drug: Erythromycin therapy
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin therapy
Study: 8426771
Drug: Local isoniazid
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local isoniazid therapy (50 mg intranodal instillation)
Study: 3305394
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil 250 mg b.i.d.
Study: 3305394
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil 500 mg b.i.d.
Study: 3305394
Drug: Cefaclor 250
Normalized name: cefaclor 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor 250 mg t.i.d.
Study: 27738640
Drug: 5-ALA with
Normalized name: 5-ALA
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-ALA with SFC (200 mg 5-ALA/229.42 mg SFC per day)
Study: 24630878
Drug: Cangrelor (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cangrelor (500 nM) with 30 mg prasugrel
Study: 24630878
Drug: Cangrelor (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cangrelor (500 nM) with 60 mg prasugrel
Study: 24630878
Drug: Prasugrel (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (30 mg) without cangrelor
Study: 24630878
Drug: Prasugrel (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (60 mg) without cangrelor
Study: 20329655
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg valsartan (test product)
Study: 20329655
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg valsartan (reference product)
Study: 18460998
Drug: Caffeine (CAF,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (CAF, 8 mg.kg body wt)
Study: 12847034
Drug: Pharmacist consultation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist consultation program (face-to-face medication reviews)
Study: 19239354
Drug: Immediate switch
Normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate switch in therapy
Study: 19239354
Drug: Delayed switch
Normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed switch (when plasma HIV-1 RNA became > or =10,000 copies/ml)
Study: 17690017
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment (CBT) targeting pain catastrophizing
Study: 15142271
Drug: Industry-sponsored drug
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Industry-sponsored drug trials
Study: 9662762
Drug: Ciprofloxacin, 500
Normalized name: Ciprofloxacin, 500 mg/5 mL oral powder for reconstitution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin, 500 mg twice daily for 3 days
Study: 9662762
Drug: Erythromycin, 500
Normalized name: Erythromycin, 500 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin, 500 mg four times daily for 7 days
Study: 9662762
Drug: Cotrimoxazole (trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotrimoxazole (trimethoprim 160 mg + sulfamethoxazole 800 mg), twice daily for 7 days
Study: 8161719
Drug: Tablets (reference)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets (reference)
Study: 2030299
Drug: Low energy
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low energy laser treatment (Mid 1500 Irradia laser, wavelength 904 nm, average power output 12 mW, peak value 8.3 W, frequency 70 Hz, pulse train 8000 Hz) applied locally to 6 sites for 30 sec each, total of 10 treatments over 2-3 weeks.
Study: 2030299
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (details not provided)
Study: 1250945
Drug: Etifoxine 300
Normalized name: etifoxine
DrugBank: Etifoxine (DB08986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etifoxine 300 mg
Study: 1250945
Drug: d‐amphetamine 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐amphetamine 5 mg
Study: 30914350
Drug: Aqueous extract
Normalized name: green tea aqueous extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous extract of saffron capsule (200 mg/day)
Study: 19125045
Drug: Epinastine 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinastine 0.05% twice a day plus rewetting drops as required (n = 75)
Study: 15848653
Drug: DAC-TAC-MMF (tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAC-TAC-MMF (tacrolimus with MMF and daclizumab induction therapy)
Study: 9385484
Drug: Tiludronate formulation
Normalized name: tiludronate
DrugBank: Tiludronic acid (DB01133)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tiludronate formulation 9O1 (400 mg/d for 84 +/- 2 days)
Study: 9385484
Drug: Tiludronate formulation
Normalized name: tiludronate
DrugBank: Tiludronic acid (DB01133)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tiludronate formulation 3C1 (400 mg/d for 84 +/- 2 days)
Study: 8737552
Drug: CRF patients
Normalized name: CRF
DrugBank: Corticorelin (DB05394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRF patients on conservative treatment (Gp II)
Study: 3232477
Drug: Constant infusion
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant infusion of a solution containing glucose (4%), sodium (40 mmol/l), and potassium (20 mmol/l) throughout the observation period
Study: 3232477
Drug: 5-hour infusion
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-hour infusion of 10% glucose daily, with potassium and sodium solution in between
Study: 28474437
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + 0.75% boric acid gel (BA group)
Study: 28474437
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + placebo gel (placebo group)
Study: 19363908
Drug: Tretinoin gel
Normalized name: Tretinoin Gel
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tretinoin gel 0.05% (n=674)
Study: 19363908
Drug: Tretinoin gel
Normalized name: Tretinoin Gel
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tretinoin gel microsphere 0.1% (n=376)
Study: 16469022
Drug: Trospium chloride
Normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trospium chloride 20 mg twice daily for 12 weeks
Study: 12964501
Drug: Tropisetron 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron 0.05 mg/kg intravenously
Study: 1828963
Drug: Cisplatin 50
Normalized name: cisplatin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 50 mg/m2 on days 1, 8, 15, and 22 of radiation therapy
Study: 6338416
Drug: Propranolol (1.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (1.7 mg/kg)
Study: 6338416
Drug: Phenobarbital (1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital (1.3 mg/kg)
Study: 25675562
Drug: Acupuncture with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture with filiform needle and warm needling therapy combined with positive functional exercise (CZ Dz)
Study: 19014765
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 100 microg twice daily (FP monotherapy)
Study: 19298635
Drug: Montelukast 5
Normalized name: montelukast 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 5 mg once daily
Study: 19014765
Drug: Combination fluticasone
Normalized name: fluticasone, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination fluticasone 100 microg AM and salmeterol twice daily
Study: 15836887
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg rimonabant
Study: 12841342
Drug: Cerivastatin 0.3
Normalized name: cerivastatin 0.3 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerivastatin 0.3 mg at the time of admission (group C+)
Study: 12841342
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (group C−)
Study: 10442494
Drug: L-arginine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine infusion (290 mg/min/1.73 m2 for 1 h) in normal volunteers
Study: 7587923
Drug: AO-128 (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: AO-128 (0.2 mg) with sucrose
Study: 7587923
Drug: AO-128 (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: AO-128 (0.03 mg/kg)
Study: 7587923
Drug: AO-128 (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: AO-128 (0.1 mg/kg)
Study: 26695796
Drug: Low frequency
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low frequency and intermediate frequency descent type treatment
Study: 26695796
Drug: Flat type
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flat type treatment
Study: 26695796
Drug: High frequency
Normalized name: ALCOHOL 0.7 mL in 1 mL TOPICAL SOLUTION [enMotion Foam High Frequency Use]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High frequency descent type treatment
Study: 26695796
Drug: Total deafness
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total deafness type treatment
Study: 21869693
Drug: GW468816 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW468816 (200 mg/d)
Study: 11465650
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride supplementation 2 g four times a day
Study: 9467039
Drug: High-dose leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose leucovorin (LV) administered weekly
Study: 9467039
Drug: Bimonthly high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimonthly high-dose LV
Study: 9467039
Drug: Weekly high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly high-dose LV with 5-fluorouracil (5-FU)
Study: 9467039
Drug: Daily x
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily x 5 LV with 5-FU
Study: 9467039
Drug: Management strategies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Management strategies for toxicity (delaying treatment, dose reduction, octreotide)
Study: 1980266
Drug: Azelastine hydrochloride
Normalized name: Azelastine Hydrochloride
DrugBank: Azelastine (DB00972)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Azelastine hydrochloride 1.1 mg
Study: 7818588
Drug: Azelastine hydrochloride
Normalized name: Azelastine Hydrochloride
DrugBank: Azelastine (DB00972)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Azelastine hydrochloride 2.2 mg
Study: 2896104
Drug: Azelastine hydrochloride
Normalized name: Azelastine Hydrochloride
DrugBank: Azelastine (DB00972)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Azelastine hydrochloride 4.4 mg
Study: 1980266
Drug: Azelastine hydrochloride
Normalized name: Azelastine Hydrochloride
DrugBank: Azelastine (DB00972)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Azelastine hydrochloride 2.2 mg and 4.4 mg
Study: 6259722
Drug: Oral Estramustine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Estramustine phosphate
Study: 6259722
Drug: Intramuscular polyestradiol
Normalized name: POLYESTRADIOL
DrugBank: Polyestradiol phosphate (DB09369)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular polyestradiol phosphate plus oral ethinyl estradiol
Study: 28499420
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (100 mcg)
Study: 25630368
Drug: Lipid-based nutritional
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nutritional supplement without additional vitamins and minerals (LNS)
Study: 25630368
Drug: Lipid-based nutritional
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nutritional supplement with additional vitamins and minerals (LNS-VM)
Study: 18355326
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine without polysorbate-20 (R)
Study: 18355326
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine with polysorbate-20 (T)
Study: 18355326
Drug: Both formulations
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both formulations of insulin glargine
Study: 8607393
Drug: Flecainide 200
Normalized name: flecainide 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide 200 mg (n = 97)
Study: 8607393
Drug: Propafenone 450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone 450 mg (n = 103)
Study: 8607393
Drug: Flecainide (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide (maximum 300 mg/day)
Study: 8607393
Drug: Propafenone (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone (maximum 900 mg/day)
Study: 28623638
Drug: Taurolock™‐HEP500 (heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taurolock™‐HEP500 (heparin 500 IU/mL, taurolidine, citrate 4%) after each hemodialysis session
Study: 25640807
Drug: Intensive/triple antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive/triple antiplatelet therapy for one month
Study: 24171182
Drug: Propranolol 90
Normalized name: propranolol hydrochloride 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 90 mg and Stabilization Splint (SS)
Study: 24171182
Drug: Propranolol 90
Normalized name: propranolol hydrochloride 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 90 mg and Non-Occlusal Splint (NOS)
Study: 17550044
Drug: Hydroxyzine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyzine (2 mg/kg 2 h before treatment and 1 mg/kg 20 min before treatment)
Study: 17550044
Drug: Midazolam (0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.50 mg/kg) mixed with hydroxyzine (1.5 mg/kg) 20 min before treatment
Study: 17550044
Drug: Chloral hydrate
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloral hydrate (50 mg/kg) mixed with hydroxyzine (1.5 mg/kg) 20 min before treatment
Study: 14762748
Drug: Phase I
Normalized name: Nuvelle TS Phase I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase I surgery (hyoid suspension, palatal surgery, and/or genioglossus advancement)
Study: 8056717
Drug: Pimobendan (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimobendan (2.5 or 5.0 mg/day)
Study: 3241254
Drug: Adrenaline (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline (15 mg/kg per min)
Study: 3241254
Drug: Saline (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (0.9% NaCl, 5.4 ml/h)
Study: 29804902
Drug: Ribociclib (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribociclib (600 mg/day on a 3-weeks-on, 1-week-off schedule) plus endocrine therapy (oral tamoxifen 20 mg daily or letrozole 2.5 mg or anastrozole 1 mg daily, both with goserelin 3.6 mg subcutaneously every 28 days)
Study: 29804902
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus endocrine therapy (oral tamoxifen 20 mg daily or letrozole 2.5 mg or anastrozole 1 mg daily, both with goserelin 3.6 mg subcutaneously every 28 days)
Study: 23938374
Drug: Chemotherapy treated
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy treated women
Study: 23938374
Drug: Treatment related
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment related toxicities (mucositis, diarrhea, decreased absolute neutrophil count, elevated glucose, cholesterol)
Study: 21449676
Drug: Antidepressants other
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants other than paroxetine
Study: 18155871
Drug: Cilostazol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol (100 mg twice daily, could be reduced to 50 mg twice daily)
Study: 10867087
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy (specifics not provided)
Study: 10867087
Drug: Calcium antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonists (specifics not provided)